Dual-Targeted Thalidomide Nanoliposomes Suppress Neutrophil-Driven Inflammation in Intestinal Behçet’s Disease

Excessive neutrophil recruitment, vascular activation, and platelet-associated inflammatory interfaces are implicated in intestinal tissue injury in intestinal Behçet's disease (intestinal BD), whereas conventional systemic therapies offer limited spatial control over drug exposure within active intestinal lesions. Here, we developed thalidomide-loaded nanoliposomes co-functionalized with a neutrophil elastase-binding peptide (NEBP) and a P-selectin-binding peptide (PSN), designated Thd-NEBP/PSN-Lip, to engage complementary activated neutrophil-associated and P-selectin-associated inflammatory interfaces. Thd-NEBP/PSN-Lip exhibited a mean hydrodynamic diameter of 116.6 ± 5.7 nm, a thalidomide encapsulation efficiency of 91.43 ± 0.71%, and reduced initial burst release, while maintaining colloidal stability during storage and simulated gastrointestinal exposure. Surface ligand density was estimated from the feed composition. Ligand-dependent interactions were observed in activated endothelial cells and neutrophil-like cells; in activated endothelial cells, liposome-associated fluorescence increased from 7.42% for Thd-Lip to 40.55% for Thd-NEBP/PSN-Lip and decreased to 1.10% following free PSN competition. Additional validation supported PSN-dependent association with activated platelets and greater inflamed-tissue association of the dual-ligand formulation than with either single-ligand formulation. In vivo, Thd-NEBP/PSN-Lip showed preferential and prolonged retention within inflamed intestinal tissues, with intestinal fluorescence remaining approximately 2.6-fold higher than that of Thd-Lip at 24 h. LC-MS/MS quantification further showed increased total intestinal thalidomide exposure and a higher intestine/plasma concentration ratio after Thd-NEBP/PSN-Lip administration. In a murine intestinal BD-like model, Thd-NEBP/PSN-Lip alleviated intestinal injury, restored colon length toward the healthy level, reduced neutrophil infiltration and local inflammatory cytokine expression, attenuated responses involving IL-17A+CD4+ and IFN-γ+CD4+ T cells, and partially restored the Foxp3+ regulatory T cell compartment. Microbiome, metabolomic, and transcriptomic analyses further indicated broader treatment-associated changes in the intestinal inflammatory microenvironment. Collectively, these findings suggest that dual-targeted nanoliposomes improve lesion-directed thalidomide delivery and suppress neutrophil-driven intestinal inflammation, supporting a pathology-guided nanotherapeutic strategy for intestinal BD.

Authors

Institutions

Publication Details

Journal
ACS Applied Materials & Interfaces
Published
2026-11-17
DOI
https://doi.org/10.1021/acsami.6c15386
Primary Topic
Nanoparticle-Based Drug Delivery
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Dual-Targeted Thalidomide Nanoliposomes Suppress Neutrophil-Driven Inflammation in Intestinal Behçet’s Disease

Kaichao Song, Peng Lei, Fujun Zeng, 郑稳生 et al.
3 links
ACS Applied Materials & Interfaces
Nanoparticle-Based Drug Delivery
article

Dual-Targeted Thalidomide Nanoliposomes Suppress Neutrophil-Driven Inflammation in Intestinal Behçet’s Disease

Kaichao Song, Peng Lei, Fujun Zeng, 郑稳生, Ya Meng, HE Shuwang, Rou Tang, Zhenhua Li, Wu Dong, Xiaochuan Tan, Yige Yang, Yujia Zhang, Kun He, Lu Lu, Shuo Chen
article en

Abstract

Excessive neutrophil recruitment, vascular activation, and platelet-associated inflammatory interfaces are implicated in intestinal tissue injury in intestinal Behçet's disease (intestinal BD), whereas conventional systemic therapies offer limited spatial control over drug exposure within active intestinal lesions. Here, we developed thalidomide-loaded nanoliposomes co-functionalized with a neutrophil elastase-binding peptide (NEBP) and a P-selectin-binding peptide (PSN), designated Thd-NEBP/PSN-Lip, to engage complementary activated neutrophil-associated and P-selectin-associated inflammatory interfaces. Thd-NEBP/PSN-Lip exhibited a mean hydrodynamic diameter of 116.6 ± 5.7 nm, a thalidomide encapsulation efficiency of 91.43 ± 0.71%, and reduced initial burst release, while maintaining colloidal stability during storage and simulated gastrointestinal exposure. Surface ligand density was estimated from the feed composition. Ligand-dependent interactions were observed in activated endothelial cells and neutrophil-like cells; in activated endothelial cells, liposome-associated fluorescence increased from 7.42% for Thd-Lip to 40.55% for Thd-NEBP/PSN-Lip and decreased to 1.10% following free PSN competition. Additional validation supported PSN-dependent association with activated platelets and greater inflamed-tissue association of the dual-ligand formulation than with either single-ligand formulation. In vivo, Thd-NEBP/PSN-Lip showed preferential and prolonged retention within inflamed intestinal tissues, with intestinal fluorescence remaining approximately 2.6-fold higher than that of Thd-Lip at 24 h. LC-MS/MS quantification further showed increased total intestinal thalidomide exposure and a higher intestine/plasma concentration ratio after Thd-NEBP/PSN-Lip administration. In a murine intestinal BD-like model, Thd-NEBP/PSN-Lip alleviated intestinal injury, restored colon length toward the healthy level, reduced neutrophil infiltration and local inflammatory cytokine expression, attenuated responses involving IL-17A+CD4+ and IFN-γ+CD4+ T cells, and partially restored the Foxp3+ regulatory T cell compartment. Microbiome, metabolomic, and transcriptomic analyses further indicated broader treatment-associated changes in the intestinal inflammatory microenvironment. Collectively, these findings suggest that dual-targeted nanoliposomes improve lesion-directed thalidomide delivery and suppress neutrophil-driven intestinal inflammation, supporting a pathology-guided nanotherapeutic strategy for intestinal BD.

ACS Applied Materials & Interfaces
Chinese Academy of Medical Sciences & Peking Union Medical College (CN), Peking Union Medical College Hospital (CN), China Medical University (CN)
Peking Union Medical College
Good health and well-being
Nanoparticle-Based Drug Delivery
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon